1005-38-5

Basic information

• Product Name: 4-Amino-6-chloro-2-(methylthio)pyrimidine
• Synonyms: 4-Pyrimidinamine, 6-chloro-2-(methylthio)-;6-Chloro-2-(methylsulfanyl)-4-pyrimidinylamine;U 8342;2-METHYLMERCAPTO-4-AMINO-AMINO-6-CHLOROPYRIMIDINE;4-AMINO-6-CHLORO-2-METHYLMERCAPTOPYRIMIDINE;4-AMINO-6-CHLORO-2-(METHYLTHIO)PYRIMIDINE;6-AMINO-4-CHLORO-2-METHYLMERCAPTOPYRIMIDINE;6-CHLORO-2-(METHYLTHIO)PYRIMIDIN-4-AMINE
• CAS NO: 1005-38-5
• Molecular Formula: C₅H₆ClN₃S
• Molecular Weight: 175.64
• EINECS: 213-734-3
• Product Categories: Sulphur Derivatives;Building Blocks;Halogenated Heterocycles;Heterocyclic Building Blocks;Pyrimidines;PyrimidinesHeterocyclic Building Blocks;Building Blocks;C4 to C5;Chemical Synthesis;Halogenated Heterocycles;Heterocyclic Building Blocks;Heterocycle-Pyrimidine series
• Mol File: 1005-38-5.mol
• Article Data: 9

Chemical Properties

• Melting Point: 130-132 °C(lit.)
• Boiling Point: 338.7°Cat760mmHg
• Flash Point: 158.6°C
• Appearance: Off-white to beige or yellow/Crystalline Powder
• Density: 1.395 (estimate)
• Vapor Pressure: 9.64E-05mmHg at 25°C
• Refractive Index: 1.6100 (estimate)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 1.11±0.10(Predicted)
• CAS DataBase Reference: 4-Amino-6-chloro-2-(methylthio)pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Amino-6-chloro-2-(methylthio)pyrimidine(1005-38-5)
• EPA Substance Registry System: 4-Amino-6-chloro-2-(methylthio)pyrimidine(1005-38-5)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 37/39-26
• WGK Germany: 3
• Hazardous Substances Data: 1005-38-5(Hazardous Substances Data)

Usage

Uses

4-Amino-6-chloro-2-(methylthio)pyrimidine is a halogenated heterocycle, a useful synthesis intermediate.

Chemical Properties

off-white to beige or yellow crystalline powder

Synthesis Reference(s)

Journal of the American Chemical Society, 77, p. 1098, 1955 DOI: 10.1021/ja01610a006

InChI:InChI=1/C5H6ClN3S/c1-10-5-8-3(6)2-4(7)9-5/h2H,1H3,(H2,7,8,9)

Upstream product

• 6299-25-8 4,6-Dichloro-2-(methylthio)pyrimidine 
• 7664-41-7 ammonia 
• 1074-41-5 2-(Methylthio)-4-hydroxy-6-aminopyrimidine 
• 1074-41-5 6-amino-2-methylsulfanylpyrimidin-4(3H)-one 

Downstream Products

• 52222-40-9 N⁴,N⁴-dimethyl-2-methylsulfanyl-pyrimidine-4,6-diyldiamine 
• 108481-08-9 N⁴-methyl-2-methylsulfanyl-N⁴-phenyl-pyrimidine-4,6-diyldiamine 
• 3289-35-8 4-Chlor-cytosin 
• 63931-22-6 5-bromo-6-chloro-2-(methylthio)pyrimidine-4-amine 
• 339016-22-7 6-chloro-N-(4-fluorophenyl)-2-(methylthio)pyrimidin-4-amine 
• 86626-97-3 (6-chloro-2-methylsulfanylpyrimidin-4-yl)phenylamine 
• 848498-96-4 tert-butyl 1-[6-amino-2-(methylthio)pyrimidin-4-yl]piperidin-4-ylcarbamate 
• 932046-86-1 2-methylsulfanyl-6-(3-trifluoromethyl-phenyl)-pyrimidin-4-ylamine 
• 3289-53-0 6-methoxy-2-methylsulfanyl-pyrimidin-4-ylamine 
• 60722-63-6 N⁴-benzyl-2-methylsulfanyl-pyrimidine-4,6-diamine 
• 1005-39-6 4,6-diamino-2-methylthiopyrimidine 
• 1004-38-2 2,4,6-triaminopyrimidine 
• 848499-17-2 tert-butyl {1-[6-(acetylamino)-2-(methylthio)pyrimidin-4-yl]piperidin-4-yl}carbamate 
• 77766-06-4 2-(methylthio)-6-phenylpyrimidin-4-amine 

Relevant articles and documents

Structure-based drug design of novel, potent, and selective azabenzimidazoles (ABI) as ATR inhibitors

Compound 13 was discovered through morphing of the ATR biochemical HTS hit 1. The ABI series was potent and selective for ATR. Incorporation of a 6-azaindole afforded a marked increase in cellular potency but was associated with poor PK and hERG ion channel inhibition. DMPK experiments established that CYP P450 and AO metabolism in conjunction with Pgp and BCRP efflux were major causative mechanisms for the observed PK. The series also harbored the CYP3A4 TDI liability driven by the presence of both a morpholine and an indole moiety. Incorporation of an adjacent fluorine or nitrogen into the 6-azaindole addressed many of the various medicinal chemistry issues encountered. (Chemical Presented).

New approach to synthesize symmetrical and unsymmetrical 6-(N-Alkyl(Aryl)amino)-and 6-(N, N-dialkyl(Aryl)amino)-2,4-bis(Alkyl(Aryl)Thio) pyrimidines as anti-platelet agents

A new and straightforward procedure has been developed for the preparation of symmetrical and unsymmetrical 6-(N-alkyl(aryl)amino)-and 6-(N,N- bisalkyl(aryl)amino)-2,4-bis(alkyl(aryl)thio)pyrimidines. The two identical or different alkylthio groups were s

THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING ALLOSTERIC KINASE INHIBITION

The present invention is directed to methods and compositions for suppressing lymphangiogenesis, angiogenesis and/or tumor growth. The methods comprise contacting the tumor with a compound that (i) stabilizes a protein kinase in the inactive state and (ii